How far to go? screening and surveillance in Barrett's esophagus

David Lieberman, R. E. Sampliner

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

There is no dispute that Barrett's esophagus (BE) is associated with an increased risk of esophageal adenocarcinoma. Detecting these cancers early can improve patient survival. But should screening be used to detect BE, or should a surveillance program monitor those already diagnosed with BE for neoplastic changes? Endoscopy and endoscopic biopsy are the only tools available for such screening and surveillance, and the cost effectiveness of either approach must be considered. Two possible solutions are discussed. First, screening could be limited to patients considered at high risk for BE and associated adenocarcinoma. With this approach, more precise risk stratification would be required. The second possible approach is to combine screening for high-risk patients and surveillance for those already diagnosed with BE. Additional outcomes data are needed to determine how often and for what length of time endoscopic surveillance should continue in a patient after several examinations are negative for adenocarcinoma.

Original languageEnglish (US)
JournalAmerican Journal of Managed Care
Volume7
Issue number1 SUPPL.
StatePublished - 2001
Externally publishedYes

Fingerprint

Barrett Esophagus
surveillance
Adenocarcinoma
Dissent and Disputes
cancer
Endoscopy
Cost-Benefit Analysis
examination
Biopsy
costs
Survival
Neoplasms

ASJC Scopus subject areas

  • Nursing(all)
  • Medicine(all)
  • Health(social science)
  • Health Professions(all)

Cite this

How far to go? screening and surveillance in Barrett's esophagus. / Lieberman, David; Sampliner, R. E.

In: American Journal of Managed Care, Vol. 7, No. 1 SUPPL., 2001.

Research output: Contribution to journalArticle

@article{e9b4ac82a1524f2c82cdec804790fe2c,
title = "How far to go? screening and surveillance in Barrett's esophagus",
abstract = "There is no dispute that Barrett's esophagus (BE) is associated with an increased risk of esophageal adenocarcinoma. Detecting these cancers early can improve patient survival. But should screening be used to detect BE, or should a surveillance program monitor those already diagnosed with BE for neoplastic changes? Endoscopy and endoscopic biopsy are the only tools available for such screening and surveillance, and the cost effectiveness of either approach must be considered. Two possible solutions are discussed. First, screening could be limited to patients considered at high risk for BE and associated adenocarcinoma. With this approach, more precise risk stratification would be required. The second possible approach is to combine screening for high-risk patients and surveillance for those already diagnosed with BE. Additional outcomes data are needed to determine how often and for what length of time endoscopic surveillance should continue in a patient after several examinations are negative for adenocarcinoma.",
author = "David Lieberman and Sampliner, {R. E.}",
year = "2001",
language = "English (US)",
volume = "7",
journal = "American Journal of Managed Care",
issn = "1088-0224",
publisher = "Ascend Media",
number = "1 SUPPL.",

}

TY - JOUR

T1 - How far to go? screening and surveillance in Barrett's esophagus

AU - Lieberman, David

AU - Sampliner, R. E.

PY - 2001

Y1 - 2001

N2 - There is no dispute that Barrett's esophagus (BE) is associated with an increased risk of esophageal adenocarcinoma. Detecting these cancers early can improve patient survival. But should screening be used to detect BE, or should a surveillance program monitor those already diagnosed with BE for neoplastic changes? Endoscopy and endoscopic biopsy are the only tools available for such screening and surveillance, and the cost effectiveness of either approach must be considered. Two possible solutions are discussed. First, screening could be limited to patients considered at high risk for BE and associated adenocarcinoma. With this approach, more precise risk stratification would be required. The second possible approach is to combine screening for high-risk patients and surveillance for those already diagnosed with BE. Additional outcomes data are needed to determine how often and for what length of time endoscopic surveillance should continue in a patient after several examinations are negative for adenocarcinoma.

AB - There is no dispute that Barrett's esophagus (BE) is associated with an increased risk of esophageal adenocarcinoma. Detecting these cancers early can improve patient survival. But should screening be used to detect BE, or should a surveillance program monitor those already diagnosed with BE for neoplastic changes? Endoscopy and endoscopic biopsy are the only tools available for such screening and surveillance, and the cost effectiveness of either approach must be considered. Two possible solutions are discussed. First, screening could be limited to patients considered at high risk for BE and associated adenocarcinoma. With this approach, more precise risk stratification would be required. The second possible approach is to combine screening for high-risk patients and surveillance for those already diagnosed with BE. Additional outcomes data are needed to determine how often and for what length of time endoscopic surveillance should continue in a patient after several examinations are negative for adenocarcinoma.

UR - http://www.scopus.com/inward/record.url?scp=0035116916&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035116916&partnerID=8YFLogxK

M3 - Article

C2 - 11225349

AN - SCOPUS:0035116916

VL - 7

JO - American Journal of Managed Care

JF - American Journal of Managed Care

SN - 1088-0224

IS - 1 SUPPL.

ER -